Adding Apalutamide Boosts PSA Control in Prostate Cancer Adding Apalutamide Boosts PSA Control in Prostate Cancer

Adding apalutamide to androgen deprivation therapy (ADT) prolongs prostate-specific antigen progression-free survival in patients with biochemically recurrent prostate cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news